11th abril 2022
H&T Presspart awarded Platinum Status in Chiesi’s ‘Value Chain Evolution’
H&T Presspart, a market leading manufacturer of respiratory drug delivery components and medical devices, is pleased to announce we have been awarded Platinum Status by Chiesi in their ‘Value Chain Evolution’ supply chain review.
H&T Presspart achieved Platinum Status, the highest award level possible with an overall score of 84/100, with only 9% of Chiesi’s suppliers achieving this rating. In the individual ratings H&T Presspart impressed in a number of categories with scores of 90/100 for Economics, 90/100 for Quality and a particularly impressive score for Customer Service of 94/100.
Julian Hemy, H&T Presspart’s Vice President- Commercial, commented ‘As a company we pride ourselves on the long term partnerships we have with our customers, and it is extremely pleasing that with one of our longest standing customers, Chiesi, we have achieved Platinum status and gained such a high score, particularly for Quality and Customer Services. As a key supplier, we look forward to continuing on this journey with Chiesi to create a sustainable supply chain’
Chiesi’s ‘Value Chain Evolution’ programme is a co-evolution process to capture strategic supplier’s contribution and to map the evolution of the entire Chiesi Eco System, including carbon neutrality targets, and to create a sustainable value chain.
Guido D’Agostino, Chiesi Head of Global Procurement, commented “We sensibly rely on H&T Presspart since many years now. I am very satisfied they reached our Platinum award for Quality and Customer Service. We are launching a substantial ecological transition across our entire value chain and we need partners like H&T Presspart following us in such a challenging path.”
Headquartered in Parma, Italy, the Chiesi Group is an international research-oriented pharmaceutical and healthcare company with more than 85 years of experience that is active in 30 countries with over 6,000 employees. To accomplish their task of improving quality of life while acting responsibly in terms of society and the environment, the Group researches, develops and markets innovative therapy solutions in the three main areas of AIR (products and services to support the breathing of newborns all the way to adults), RARE (treatment of patients with rare and very rare diseases) and CARE (products and services to support special treatments and for consumer self-care). In 2019, Chiesi became the largest B Corp-certified pharmaceutical company in the world. The global B Corp movement fosters companies as a force for good.
About H&T Presspart
H&T Presspart is a market leader in the design and manufacture of respiratory drug delivery systems, with 50 years’ experience and a worldwide reputation for competence, quality and innovation in the pharmaceutical market. H&T Presspart’s New Product Development Center (NPDC) & Inhalation Product Technology Centre (IPTC) support new product developments and strategic initiatives with our customers. H&T Presspart has 4 European manufacturing sites with additional sales offices in China, India, the U.S.A. and Uruguay. For more information, please visit www.presspart.com.